cuibono2 | 5 points | Apr 16 2021 23:12:01

ivermectin prophylaxis failure in Singapore trial

https://www.ijidonline.com/article/S1201-9712(21)00345-3/pdf

permalink

[-] MacroTurtleLibido | 10 points | Apr 17 2021 01:14:33

OFFS

Talk about burying the good news.

Look at table 2 on page 30.

Ivermectin *significantly* reduced acute respiratory symptoms (p = 0.012) and symptomatic Covid-19 ( p = 0.0034).

Not sure why you have to hunt for these things, but you do.

permalink

[-] runderwo | 6 points | Apr 17 2021 02:53:58

If these results can be generalized, this is even actually excellent news for those wondering if ivermectin prophylaxis will interfere with development of vaccine-based antibodies. If it reliably converts viral encounters into asymptomatic infections (detectable only with PCR), that means long-lasting T-cell immunity would have an opportunity to develop through community exposure.

permalink

[-] stereomatch | 1 points | Apr 17 2021 09:35:07

If these results can be generalized, this is even actually excellent news for those wondering if ivermectin prophylaxis will interfere with development of vaccine-based antibodies. If it reliably converts viral encounters into asymptomatic infections (detectable only with PCR), that means long-lasting T-cell immunity would have an opportunity to develop through community exposure.

Yes, after you pointed out the reduced symptoms on page 30, I noticed the discrepancy between reduced symptoms but higher PCR/antibody test positives as well.

Which does seem to support development of herd immunity.

As mentioned in this comment:

https://www.reddit.com/r/ivermectin/comments/msfrxg/positive_impact_of_oral_hydroxychloroquine_and/gutma8q

permalink

[-] MacroTurtleLibido | 2 points | Apr 18 2021 12:30:05

Well, with Remdesivir, a secondary endpoint (days in hospital) got elevated to be the primary mid-stream and with a super-weak-ass result even then (only for the 5 day course, not the ten, and only for a certain level of O2 flow), was promoted and made standard of care.

Just sayin...

Edit: Oops. Was replying to comment below.

Unfortunately, it's a secondary endpoint in the trial, not the primary endpoint (reduced infection rate). So, it will get buried...

permalink

[-] MacroTurtleLibido | 1 points | Apr 18 2021 12:31:34

that means long-lasting T-cell immunity would have an opportunity to develop through community exposure.

Say, that's a great point. Deserves to be studied!

permalink

[-] cuibono2 | 5 points | Apr 17 2021 01:31:08

What in the world!! Thanks.

this is another hit job.

permalink

[-] jpdowlin | 2 points | Apr 18 2021 07:16:03

Unfortunately, it's a secondary endpoint in the trial, not the primary endpoint (reduced infection rate). So, it will get buried...

permalink

[-] stereomatch | 5 points | Apr 16 2021 23:59:49

Check this post:

https://www.reddit.com/r/ivermectin/comments/msfrxg/positive_impact_of_oral_hydroxychloroquine_and/ Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial (April 14, 2021) - also suggests ivermectin less effective than HCQ - but ivermectin was given only once while HCQ was given daily over a period of 42 days

permalink

[-] cuibono2 | 1 points | Apr 16 2021 23:14:18

It should be noted that the trial has severe lmitations that the authors do disclose

permalink

[-] iResistDe4iAm | 1 points | Apr 17 2021 03:01:25

https://www.ijidonline.com/article/S1201-9712(21)00345-3/pdf00345-3/pdf)

Link is broken.

New URL link is: https://www.ijidonline.com/article/S1201-9712(21)00345-3/pdf

permalink